Chang AE - Search Results

1

Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.

Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, Chang AE, Hunter CA, Fox JC, Trinchieri G, Lee WM. Coughlin CM, et al. Among authors: chang ae. J Clin Invest. 1998 Mar 15;101(6):1441-52. doi: 10.1172/JCI1555. J Clin Invest. 1998. PMID: 9502787 Free PMC article.

2

Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression.

Kurzawa H, Wysocka M, Aruga E, Chang AE, Trinchieri G, Lee WM. Kurzawa H, et al. Among authors: chang ae. Cancer Res. 1998 Feb 1;58(3):491-9. Cancer Res. 1998. PMID: 9458095

3

Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.

Aruga E, Aruga A, Arca MJ, Lee WM, Yang NS, Smith JW 2nd, Chang AE. Aruga E, et al. Among authors: chang ae. Cancer Gene Ther. 1997 May-Jun;4(3):157-66. Cancer Gene Ther. 1997. PMID: 9171934

4

Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.

Aruga A, Aruga E, Chang AE. Aruga A, et al. Among authors: chang ae. Cancer Res. 1997 Aug 1;57(15):3230-7. Cancer Res. 1997. PMID: 9242454

5

Interferon-gamma-inducing factor elicits antitumor immunity in association with interferon-gamma production.

Tan J, Crucian BE, Chang AE, Aruga E, Aruga A, Dovhey SE, Tanigawa K, Yu H. Tan J, et al. Among authors: chang ae. J Immunother. 1998 Jan;21(1):48-55. doi: 10.1097/00002371-199801000-00006. J Immunother. 1998. PMID: 9456436

6

Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.

Aruga A, Aruga E, Cameron MJ, Chang AE. Aruga A, et al. Among authors: chang ae. J Leukoc Biol. 1997 Apr;61(4):507-16. doi: 10.1002/jlb.61.4.507. J Leukoc Biol. 1997. PMID: 9103238 Free article.

7

Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity.

Aruga A, Tanigawa K, Aruga E, Yu H, Chang AE. Aruga A, et al. Among authors: chang ae. Cancer Gene Ther. 1999 Jan-Feb;6(1):89-95. doi: 10.1038/sj.cgt.7700010. Cancer Gene Ther. 1999. PMID: 10078968

8

Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role.

Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE. Aruga A, et al. Among authors: chang ae. J Immunol. 1997 Jul 15;159(2):664-73. J Immunol. 1997. PMID: 9218581

9

CD95-mediated tumor recognition by CD4+ effector cells in a murine mammary model.

Aruga E, Tanigawa K, Aruga A, Arai H, Smith JW 2nd, Nickoloff BJ, Nabel GJ, Chang AE. Aruga E, et al. Among authors: chang ae. J Immunother. 2000 Mar-Apr;23(2):225-34. doi: 10.1097/00002371-200003000-00007. J Immunother. 2000. PMID: 10746549

10

Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model.

Tan J, Newton CA, Djeu JY, Gutsch DE, Chang AE, Yang NS, Klein TW, Hua Y. Tan J, et al. Among authors: chang ae. Cancer Res. 1996 Aug 1;56(15):3399-403. Cancer Res. 1996. PMID: 8758901

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

346 results

Search Page

Filters